ABSTRACT
Objective:To investigate the effects of butylphthalide combined with ozagrel sodium on the National Institutes of Health Stroke Scale (NIHSS) score, activities of daily living (ADL) score, and coagulation function in patients with acute cerebral infarction.Methods:Ninety-four patients with acute cerebral infarction who were admitted to Gujiao Medical Group Central Hospital from January 2019 to November 2021 were included in this study. They were randomly assigned to undergo treatment with either ozagrel sodium (control group, n = 47) or butylphthalide combined with ozagrel sodium (observation group, n = 47) for 14 consecutive days. Before and after treatment, NIHSS score, ADL score, coagulation function (thrombin time, prothrombin time, D-dimer, activated partial thrombin time), bilateral middle cerebral artery blood flow status (mean blood flow velocity (Vm), resistance index, pulsatility index), brain tissue damage factor (brain natriuretic peptide, neuron-specific enolase, S100 β protein) and the incidence of adverse drug reactions were compared between the two groups. Results:Before treatment, there were no significant differences in NIHSS and ADL scores between the two groups (both P > 0.05). After treatment, the NIHSS score was significantly lower in the observation group than that in the control group [(8.70 ± 1.62) points vs. (9.45 ± 1.2) points, t = 2.51, P < 0.05]; the ADL score was significantly higher in the observation group than that in the control group [(65.15 ± 7.41) points vs. (61.20 ± 6.32) points, t = 2.78, P < 0.05]. Before treatment, there were no significant differences in thrombin time, prothrombin time, D-dimer, and activated partial thrombin time between the two groups (all P > 0.05). After treatment, thrombin time, prothrombin time, and activated partial thrombin time were significantly higher in the observation group than those in the control group ( t = 4.34, 3.00, 2.63, all P < 0.05). After treatment, D-dimer level in the observation group was significantly lower than that in the control group ( t = 3.39, P < 0.05). Before treatment, mean blood flow velocity, resistance index, and pulsatility index were similar between the two groups (all P > 0.05). After treatment, the mean blood flow velocity in the observation group was significantly higher than that in the control group ( t = 3.23, P < 0.05). The pulsatility index and resistance index were significantly lower in the observation group than those in the control group ( t = 2.14, 3.16, both P < 0.05). Before treatment, there were no significant differences in brain natriuretic peptide, neuron-specific enolase, and S100 β protein levels between the two groups (all P > 0.05). After treatment, brain natriuretic peptide, neuron-specific enolase, and S100 β protein levels in the observation group were significantly lower than those in the control group ( t = 3.09, 2.18, 3.33, all P < 0.05). There was no significant difference in incidence of adverse reactions between the observation and control groups [6.38% (3/47) vs. 2.13% (1/47), P > 0.05]. Conclusion:Butylphthalide combined with ozagrel sodium for the treatment of acute cerebral infarction can reduce neurological dysfunction and brain tissue injury, and improve coagulation function, hemodynamic state of the middle cerebral artery, and activities of daily life, without increasing adverse reactions.
ABSTRACT
Objective: To study the activity of ozagrel sodium alone and in combination with the atypical antipsychotic drug on Red blood cell distribution width (RDW-CV) along with different doses and their comparison in rats. Method: This experimental study consisted of 120 albino rats of both gender, they were of 310-350 g, there were 10 groups which consists of each of 12 rats (n=12). Rats were treated with an accurate dose of ozagrel and atypical antipsychotic (Zuclopenthixol cis isomer of clopenthixol) alone and in combination for 3-weeks (21 days). We obtained blood sample at 0, 7th, 14th and last day of the study. Red blood distribution widths were measured from blood tests by utilizing standard medical laboratory technique. Red blood cell distribution width (RDW-CV) was measured by using the coefficient of variation indicator. Results were gathered and summarized by applying statistics. The comparison was formed between all days value to zero-day. Results: Minimum dose treated groups by both medications showed an increase and RDW-CV, but maximum dose showed p<0.001 decreases in RDW-CV in individual groups of drugs treatment and in case of RDW-CV maximum dose showed an increasing trend with p<0.001 in the combination groups. Conclusion: Maximum dose of ozagrel may cause a decrease in RDW-CV alone and it may cause an increase in (RDW-CV) with a combination of atypical antipsychotic drug.
ABSTRACT
Objective To evaluate the effect of Qixuoxue Huoxue Tongluo decoction combined with ozagrel sodium on cerebral thrombosis and to improve cerebral ischemia-reperfusion injury. Methods 106 patients of cerebral thrombosis from April 2015 to April 2016 were divided into control group and observation group, each group of 53 patients. The patients in the control group were treated with ozagrel sodium for reperfusion. The observation group was treated with Qixiqi Huoxue Tongluo decoction and ozagrel sodium for treatment. Resulrs The levels of inflammatory factors (hs-CRP, TNF-α, etc.) in the observation group were lower than those in the observation group (P<0.05), and the two groups were compared with the observation group (P<0.05). The adverse effects of NIHSS and ADL were higher than those of the control group (P<0.05). The adverse effects of NIHSS and ADL were significantly lower than those of the control group (P<0.05) ; Conclusion Qixie Huoxue Tongluo Decoction combined with ozagrel sodium for cerebral thrombosis patients have a good therapeutic effect, for cerebral ischemia and reperfusion injury also have some improvement.
ABSTRACT
Objective To evaluate the effect of Qixuoxue Huoxue Tongluo decoction combined with ozagrel sodium on cerebral thrombosis and to improve cerebral ischemia-reperfusion injury. Methods 106 patients of cerebral thrombosis from April 2015 to April 2016 were divided into control group and observation group, each group of 53 patients. The patients in the control group were treated with ozagrel sodium for reperfusion. The observation group was treated with Qixiqi Huoxue Tongluo decoction and ozagrel sodium for treatment. Resulrs The levels of inflammatory factors (hs-CRP, TNF-α, etc.) in the observation group were lower than those in the observation group (P<0.05), and the two groups were compared with the observation group (P<0.05). The adverse effects of NIHSS and ADL were higher than those of the control group (P<0.05). The adverse effects of NIHSS and ADL were significantly lower than those of the control group (P<0.05) ; Conclusion Qixie Huoxue Tongluo Decoction combined with ozagrel sodium for cerebral thrombosis patients have a good therapeutic effect, for cerebral ischemia and reperfusion injury also have some improvement.
ABSTRACT
Objective To explore the clinical application effect of Shuxuening combined with ozagrel sodium in the treatment of cerebral infarction patients with psychological intervention.Methods120 patients with cerebral infarction were randomly divided into observation group and control group from January 2015 to June 2016.The control group was treated with intravenous ozagrel sodium and psychological intervention.The observation group was treated with control group based on the use of Shuxuening.ResultsThe clinical efficacy in the observation group was significantly higher than in the control group (P<0.05).The incidence of complications in the observation group was significantly lower than that in the control group (P<0.05).ConclusionThe combination of Shuxuening combined with ozagrel sodium and psychological intervention in the treatment of cerebral infarction, can effectively improve the patient's treatment efficiency, improve the physiological and psychological status of patients, and effectively reduce the treatment of patients with complications.
ABSTRACT
Objective To observe the clinical effect of sodium ozagrel combined with cinepazide treatment of cerebral arteriosclerosis , and the influence on hemorheology and blood lipid.Methods 112 cases of arteriosclerosis in patients with cerebral infarction were randomly selected from January 2015 to January 2016 in our hospital, and were randomly divided into observation group and control group ,56 cases in each group, the control group were treated with cinepazide treatment, patients in the observation group was combined with ozagrel sodium, clinical curative effect and blood rheology were compared between the two groups study, blood lipid.Results The observation group the total efficiency was significantly higher than the control group ( P<0.05 ) .After treatment, compared with before treatment, blood rheology parameters and blood lipid levels of two groups were significantly improved ( P<0.05 ) , and the patients in the observation group improved the hemorheological parameters and blood lipid level was significantly better than the control group ( P<0.05 ) .Conclusion Ozagrel sodium combined with cinepazide maleate in the treatment of cerebral arteriosclerosis process,can significantly improve the hemorheological parameters and blood lipids, and the clinical curative effect.
ABSTRACT
Objective To evaluate the clinical efficacy of urinary kallidinogenase combined with sodium ozagrel on acute cerebral infarction.Methods Totally 170 cases of acute cerebral infarction were randomly and equally divided into control group and treatment group.The control group was treated with ozagrel sodium while the treatment group was given urinary kallidinogenase combined with ozagrel sodium.The clinical efficacy, HINSS score, infarct volume, blood rheology and adverse reactions of the two groups were observed.Results There was no significant difference in such general data as gender, age, site of disease and complications between the two groups (P>0.05).The efficacy of the treatment group was significantly better than that of the control group (Z=-2.28, P=0.02).The NIHSS score before and after treatment was (23.38±3.24) vs (12.22±7.17) respectively in the control group,and (23.18±2.96) vs (9.16±6.95) in the treatment group.The effect in the treatment group was better than in the control group (t=2.83,P<0.05).The infarct volume before and after treatment was (5.99±0.60) vs (5.00±0.34)respectively in control group, and(5.99+0.62) vs (4.00±0.21)in the treatment group.The effect in the treatment group was better than in the control group (t=23.11,P<0.05).Blood rheology indexes, fibrinogen, plasma viscosity, whole blood low shear viscosity and whole blood viscosity improvement in the treatment group were better than those in the control group (t=14.67,7.35,19.70和5.33,P<0.05).The two groups were not significantly different in the incidence of adverse reactions.Conclusion Yuri Klein combined with ozagrel sodium can effectively treat acute cerebral infarction by repairing the damaged neurons and improving the prognosis of patients,without obvious adverse reactions.It is worthy of clinical promotion.
ABSTRACT
OBJECTIVE:To observe clinical efficacy and safety of escitalopram combined with ozagrel sodium for elderly pa-tients with acute cerebral infarction complicated with anxiety and depression. METHODS:140 elderly patients with acute cerebral infarction complicating with anxiety and depression were divided into control group and observation group according to random number table method,with 70 cases in each group. Control group received routine treatment and Sodium ozagrel for injection 40-80 mg added into 0.9% Sodium chloride injection 500 ml,ivgtt,bid. Observation group was additionally given Escitalopram tablet 10 mg,qd. Both groups received treatment for 8 weeks. HAMA,HAMD,NIHSS and BI were compared between 2 groups before and after treatment,and clinical efficacy and the occurrence of ADR were observed. RESULTS:There was no statistical sig-nificance in HAMA,HAMD,NIHSS,BI before treatment and NIHSS,BI 1 week of after treatment between 2 groups(P>0.05). HAMA and HAMD of observation group 1,4,8 weeks after treatment,and NIHSS and BI of it 4,8 weeks after treatment were improved significantly;above indexes of control group were improved significantly 4,8 weeks after treatment,and the observation group was better than the control group,with statistical significance (P0.05). CONCLUSIONS:Escitalopram combined with ozagrel so-dium is significantly effective for elderly patients with acute cerebral infarction complicated with anxiety and depression,and can significantly improve anxiety,depression and neurological function with good safety.
ABSTRACT
Objective To study the treatment effect of Ozagrel sodiumin on plasma levels of BNP and IL-18in patients with unstable angina pectoris. Methods 106 patients with unstable angina pectoris were treated randomly with routine therapy(n =40) and with routine therapy plus Ozagrel sodium(n = 66) for 2 weeks. Before and after 2weeks of the therapy,the changes of BNP and IL-18 were measured. Results After 2 weeks,the levels of BNP and IL-18 in routine therapy group and Ozagrel sodium treatment group were decreased than those before treatment,but after 2 weeks of the therapy,BNP and IL-18 were significantly decreased in candesartan treatment group compared with those in the control group(P ＜0. 05). Conclusion On the basic of general treatment,using the Ozagrel sodium could lower the serum levels of BNP and IL-18 in UAP,and improve stability of atherosclerosis plaque.
ABSTRACT
Objective To observe the clinical effect of Ozagrel sodium with ultrasonic therapy in patients with acute cerebral infarction (ACI). Methods Eighty-three ACI patients were randomly divided into 2 groups: ultra-sortie therapy group(n=42) received Ozagrel sodium and ultrasonic therapy, whereas control group(n = 41) only ac-ecpted the Ozagrel sodium for injection. Both two groups were under conventional treatment. The level of laboratory in-dex and the neurological impairment were detected before and after treatment. And the clinical effect were detected in the end of the treatment. Results The neurological impairment and the clinical effect defected after therapy in both groups, had statistical difference(P < 0. 05), especially in the ultrasonic therapy group. Conclusion Ozagrel sodium with ultrasonic therapy in patients with ACI could promote recovery of the neurological function, thus increase clinical effect.